The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
Opdivo (nivolumab) given in combination with Yervoy (ipilimumab) is now approved by the Food and Drug Administration (FDA) for the treatment of patients with liver cancer, or hepatocellular carcinoma (HCC), who have already been treated with the chemotherapy drug sorafenib. Read More ›
The combination of Lenvima (lenvatinib), an oral kinase inhibitor, and the immunotherapy Keytruda (pembrolizumab), a PD-1 inhibitor, showed promising benefits for the treatment of patients with liver cancer (or hepatocellular carcinoma) that cannot be removed by surgery (unresectable). Read More ›
In May 2020, the FDA approved the combination of 2 immunotherapies for patients with metastatic hepatocellular carcinoma (liver cancer) who have not received systemic therapy and cannot be treated by surgery. Read More ›
Maria Falzone is a comedian and creator of “SEX RULES” talk, who is facing a rare and terminal liver cancer. She wants to be remembered as the person who changed the conversation around sex and sexuality. Read More ›
Unlike many types of cancers, the number of new cases of liver cancer, specifically hepatocellular carcinoma—the most common type of liver cancer—is increasing in the US. Read about the pressures, including the unmet needs, of caregivers of those affected by liver cancer. Read More ›